FIELD: biotechnology.
SUBSTANCE: invention relates to a screening method for genetic modifiers of tau protein aggregation, involving: providing a population of cells comprising a Cas protein, a first repetitive tau protein domain associated with a first reporter, and a second repetitive tau protein domain associated with a second reporter, introducing into said cell population a library containing a plurality of guide RNAs which target a plurality of genes, culturing said cell population, bringing said genetically modified cell population into contact with a tau protein seeding agent, culturing said seeded cell population, as well as determining the content of each of said plurality of guide RNAs. Also disclosed is a method of screening with respect to genetic modifiers of tau protein aggregation, comprising: providing a population of cells containing the chimeric Cas protein, a first repetitive domain of the tau protein associated with a first reporter, and a second repetitive tau protein domain associated with a second reporter, introducing into said cell population a library containing a plurality of guide RNAs which target the plurality of genes, culturing said cell population, bringing said genetically modified cell population into contact with a tau protein seeding agent, culturing said seeded cell population to enable formation of tau protein aggregates, wherein aggregates of a first repetitive tau protein domain and a second repetitive tau protein domain are formed in a subpopulation of said seeded cell population to form an aggregation positive cell population, as well as determining the content of each of said plurality of guide RNAs in said aggregation-positive cell population.
EFFECT: invention is effective for screening with respect to genetic modifiers of tau-protein aggregation.
28 cl, 29 dwg, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRISPR/CAS PLATFORM FOR EXCLUSIVE SCREENING FOR DETECTING GENETIC VULNERABILITIES ASSOCIATED WITH TAU PROTEIN AGGREGATION | 2020 |
|
RU2808829C2 |
| CAS-EXPRESSING MOUSE EMBRYONIC STEM CELLS, AND MICE AND THEIR USE | 2018 |
|
RU2782358C2 |
| NON-HUMAN ANIMALS CONTAINING HUMANISED ALBUMIN LOCUS | 2020 |
|
RU2815514C2 |
| NEW ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2777988C2 |
| DELIVERY, CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND USE IN THERAPY | 2013 |
|
RU2721275C2 |
| METHODS AND COMPOSITIONS FOR ASSESSMENT OF MEDIATED CRISPR/CAS DESTRUCTION OR CUTOUT AND INDUCED CRISPR/CAS RECOMBINATION WITH EXOGENEOUS DONOR NUCLEIC ACID IN VIVO | 2018 |
|
RU2782356C2 |
| CRISPR/CAS9 TYPE II GENOME EDITING SYSTEM AND ITS USE | 2022 |
|
RU2794774C1 |
| DELIVERY, CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED ACTION AND MODELING OF DISEASES AND DISORDERS OF POSTMITOTIC CELLS | 2014 |
|
RU2725502C2 |
| TOOL FOR CUTTING DOUBLE-STRANDED DNA USING CAS12D PROTEIN FROM KATANOBACTERIA AND HYBRID RNA PRODUCED BY FUSION OF GUIDE CRISPR RNA AND SCOUT RNA | 2020 |
|
RU2771626C1 |
| DELIVERY, USE AND USE IN THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETED ACTION ON DISORDERS AND DISEASES USING VIRAL COMPONENTS | 2014 |
|
RU2716421C2 |
